

Mintz Life Sciences Deal Activity (October – December 2020)

January 19, 2021 | Article |

VIEWPOINT TOPICS

- Life Sciences

RELATED PRACTICES

RELATED INDUSTRIES

- Life Sciences

Mergers & Acquisitions

- Represented **Neurotrope, Inc.** in its reverse merger with Metuchen Pharmaceuticals, LLC to form Petros Pharmaceuticals (December 2020)
 - Simultaneously represented Neurotrope in the spin-off of substantially all of Neurotrope's existing assets, operations and liabilities, except for certain cash retained in accordance with the terms of the Merger Agreement, into a separately traded public company
- Represented **F-Star Therapeutics** in its reverse merger with Spring Bank Pharmaceuticals (November 2020)
- Represented **Athenen Therapeutics** in its merger with Eliem Therapeutics (October 2020)

Venture Capital

- Represented **Matrix Capital Management** in its \$15M investment in AltPep Corporation (December 2020)
- Represented **Antharis Therapeutics, Inc.** in its \$5.2M Series Seed financing led by Bionext Ltd. (December 2020)
- Represented **DxLab Inc.** in its \$4M Series Seed Preferred Stock financing led by Neoteny and E14 (December 2020)
- Represented **Avilar Therapeutics, Inc.** in its \$60M Series Seed financing (December 2020)
- Represented **Hopewell Therapeutics** in its \$500K Convertible Note financing (December 2020)
- Represented **NanoView Biosciences** in its \$6M extension of its Series B financing from a mix of existing and new investors (December 2020)
- Represented **PanTher Therapeutics, Inc.** in its \$1M extension of its Series A financing led by Angel Physicians Fund, LLC and Sayan Bioventure IV, LLC (November 2020)
- Represented **Endotronix, Inc.** in its \$15M extension of its Series D financing, bringing the total for the round to \$70M (November 2020)
- Represented **DoubleRainbow Biosciences** in its \$30M Series B financing led by Gaorong Capital (October 2020)

Capital Markets

Represented the issuer:

- Represented **ImmunoGen, Inc.** in its \$150M at-the-market offering with Jefferies LLC acting as sales agent (December 2020)
- Represented **SELLAS Life Sciences Group, Inc.** in its \$16.2M registered direct offering with Maxim Group LLC acting as the placement agent (December 2020)
- Represented **Cyclacel Pharmaceuticals, Inc.** in its \$7M registered direct offering and concurrent private placement (December 2020)
- Represented **Fulgent Genetics** in its \$175M at-the-market offering with Piper Sandler & Co., BTIG, LLC and Oppenheimer & Co. Inc. acting as sales agents (November 2020)
- Represented **DermTech, Inc.** in its \$50M at-the-market offering with Cowen and Company LLC acting as sales agent (November 2020)
- Represented **Evoform Biosciences, Inc.** in its \$25M Convertible Note transaction with Adjuvant Capital (October 2020)

Represented the underwriters:

- Represented the underwriters in the \$147M public offering of **Curis, Inc.** underwritten by H.C. Wainwright & Co., LLC, Laidlaw & Company (UK) Ltd., Cantor Fitzgerald & Co. and JonesTrading Institutional Services, LLC (December 2020)

- Represented the underwriters in the \$3.2M Regulation A initial public offering of **Scopus BioPharma Inc.** underwritten by The Benchmark Company, LLC and Joseph Gunnar & Co., LLC (December 2020)
- Represented the underwriters in the \$80M initial public offering of **Galecto, Inc.** underwritten by BofA Securities, SVB Leerink, Credit Suisse and Kempen & Co. (November 2020)
- Represented the underwriters in the \$40M public offering of **Forte Biosciences, Inc.** underwritten by Truist Securities, Inc., Ladenburg Thalmann & Co. Inc., Chardan Capital Markets, LLC and Brookline Capital Markets, LLC (October 2020)
- Represented the underwriters in the \$9.5M public offering of **Isoray, Inc.** underwritten by Oppenheimer & Co. Inc. (October 2020)
- Represented the underwriters in the \$190M initial public offering of **Praxis Precision Medicines, Inc.** underwritten by Cowen, Evercore ISI, Piper Sandler, Wedbush PacGrow and Blackstone Capital Markets (October 2020)
- Represented the underwriters in the \$6.6M public offering of **Artelo Biosciences, Inc.** underwritten by Ladenburg Thalmann & Co. Inc. (October 2020)

Represented the sales agent / placement agent:

- Represented the sales agent in a \$50M at-the-market offering of **Rezolute, Inc.** with Oppenheimer & Co. Inc. acting as sales agent (December 2020)
- Represented the sales agents in a \$25M at-the-market offering of **VolitionRx Limited** with Cantor Fitzgerald & Co. and Oppenheimer & Co. Inc. acting as sales agents (November 2020)

[View Deal Activity from April – June 2020](#)

[View Deal Activity from July – September 2020](#)

[View Deal Activity from January – March 2021](#)

[View Deal Activity from April – June 2021](#)

Authors